Three peptides lead most online conversation about growth hormone optimization: sermorelin, ipamorelin, and CJC-1295. They get grouped together as “growth hormone peptides,” and patients often assume they are more or less interchangeable. They are not. They work through different mechanisms, they release growth hormone in different patterns, they have different dosing schedules, and they suit different patients.
Understanding how they actually differ matters, because matching the wrong peptide to the wrong goal produces disappointing results or unnecessary side effects. This is a clinician-oriented comparison of what these three peptides do and who each one fits.
The Two Pathways That Trigger Growth Hormone
Your pituitary gland releases growth hormone in response to two different signals, and these peptides work on one or the other.
The first pathway is the GHRH receptor. Growth hormone-releasing hormone (GHRH) is the primary “go” signal from the hypothalamus. Peptides that mimic GHRH bind this receptor and prompt the pituitary to release growth hormone. Sermorelin and CJC-1295 both work this way.
The second pathway is the ghrelin receptor, also called the growth hormone secretagogue receptor (GHS-R). Ghrelin is best known as a hunger hormone, but it also stimulates growth hormone release through this separate receptor. Peptides that activate this receptor are called growth hormone secretagogues. Ipamorelin works this way.
The important clinical point is that these two pathways are synergistic. Activating both at once produces more growth hormone release than activating either alone. This is why GHRH peptides and ghrelin-pathway peptides are frequently combined. They are not redundant. They amplify each other.
Sermorelin
Sermorelin is a GHRH analog. Specifically, it is a fragment representing the active portion of natural GHRH. It binds the GHRH receptor and stimulates the pituitary to release growth hormone in a natural, pulsatile pattern.
Sermorelin has a short half-life, meaning it acts quickly and clears quickly. This produces a pulse of growth hormone that mimics the body’s own natural release pattern. Because the pulse is brief and physiological, sermorelin is often described as a gentle, natural-feeling option.
Sermorelin was the first generation of these pituitary-stimulating peptides to see wide clinical use, and it has a longer track record than most. It also has a distinctive regulatory position: it was previously an FDA-approved product (marketed as Geref, a diagnostic agent) before being voluntarily withdrawn from the market, and that prior-approval history has given it a more stable standing for compounding than most other peptides. We covered the regulatory landscape in the post on the FDA peptide crackdown. For patients wanting a gentle, well-established GHRH peptide, sermorelin is often the starting point.
CJC-1295 (Without DAC)
CJC-1295 without DAC is also a GHRH analog, but it is modified to resist the enzymatic breakdown that clears sermorelin quickly. This gives it a somewhat longer half-life than sermorelin while still producing a pulsatile growth hormone release.
The practical effect is a stronger and slightly more sustained GHRH signal than sermorelin, while keeping the pulsatile pattern that mimics natural physiology. This version of CJC-1295 is the one commonly combined with a ghrelin-pathway peptide like ipamorelin, because the two together drive a more robust pulse than either alone.
The “without DAC” designation matters and leads directly to the next point, because there is another version of CJC-1295 that behaves very differently.
CJC-1295 With DAC
CJC-1295 with DAC (drug affinity complex) is a different molecule in its behavior. The DAC modification allows it to bind to albumin in the blood, dramatically extending its half-life to a matter of days rather than minutes or hours.
This changes the entire release pattern. Instead of producing a natural pulse, CJC-1295 with DAC produces a sustained elevation of growth hormone signaling over an extended period. This is sometimes called a “bleed” of growth hormone rather than a pulse.
The trade-off is significant. The body’s natural growth hormone release is pulsatile for a reason, and sustained elevation departs from that physiology. Sustained signaling can come with a different side effect profile, including more potential for fluid retention and other growth hormone-related effects. Some clinicians prefer to avoid the DAC version specifically because pulsatile release is more physiological. The choice between the two versions of CJC-1295 is a real clinical decision, not a technicality.
Ipamorelin
Ipamorelin works on the other pathway. It is a ghrelin receptor agonist, a growth hormone secretagogue. Rather than mimicking GHRH, it activates the second growth hormone release pathway.
Ipamorelin’s main appeal is its selectivity. Some older peptides in the ghrelin-pathway category also raised cortisol and prolactin, which is undesirable. Ipamorelin stimulates growth hormone release with minimal effect on cortisol or prolactin, making it a cleaner option within its class. It produces a pulse of growth hormone and has a relatively short half-life.
Because ipamorelin works on a different receptor than the GHRH peptides, it is most often used in combination with one of them rather than alone. The combination is the point.
Why Ipamorelin and a GHRH Peptide Are Often Combined
The most common growth hormone peptide protocol pairs a GHRH peptide (usually CJC-1295 without DAC, sometimes sermorelin) with ipamorelin. The logic is the synergy between the two pathways.
The GHRH peptide provides the “go” signal on one receptor. Ipamorelin provides a “go” signal on the other. Together, they produce more growth hormone release than either alone, while keeping the release pulsatile and physiological. The combination lets a lower dose of each achieve a stronger effect, which can also mean fewer side effects than pushing a single peptide hard.
This is why you rarely see ipamorelin prescribed by itself, and why the “CJC-1295 plus ipamorelin” combination is so common. It is not marketing. It reflects the actual receptor biology.
Dosing and Timing
The timing of these peptides is built around the body’s own growth hormone rhythm. Growth hormone is released in the largest natural pulse during deep sleep, so many protocols dose before bed to align with and amplify that natural pulse.
For the pulsatile peptides (sermorelin, CJC-1295 without DAC, ipamorelin), dosing on an empty stomach matters, because food, particularly carbohydrates and fats, can blunt the growth hormone response. A before-bed dose on an empty stomach, timed to the natural nighttime pulse, is a common approach. Some protocols use split dosing to create multiple pulses.
For CJC-1295 with DAC, the sustained release means timing is less about matching a specific pulse and more about maintaining the elevated signal, which is part of why it behaves so differently.
The right dosing and timing depend on the specific peptides chosen and the patient’s goals, and they should be set by a clinician rather than guessed at.
Matching the Peptide to the Patient
Here is the practical matching logic.
Sermorelin suits a patient who wants a gentle, pulsatile, well-established option with a more stable regulatory standing. It is often the starting point for growth hormone support.
CJC-1295 without DAC plus ipamorelin suits a patient who wants a stronger but still pulsatile and physiological response. This combination is the workhorse of growth hormone peptide protocols.
CJC-1295 with DAC suits a narrower set of situations where sustained elevation is specifically desired, and it comes with the trade-offs of departing from pulsatile physiology. Many clinicians use it cautiously or prefer the pulsatile options.
The choice depends on the goal (sleep quality, recovery, body composition, general growth hormone support), the patient’s response, tolerance for dosing frequency, and side effect considerations. There is no single best peptide. There is a best fit for a given patient and goal.
Monitoring
All growth hormone peptides require monitoring, regardless of which one is chosen. The central marker is IGF-1, which reflects growth hormone activity. The goal is to keep IGF-1 in an appropriate range, not to maximize it, because IGF-1 is a growth signal and excessive levels raise concerns over time. We discussed the IGF-1 and cancer-surveillance conversation in the post on tesamorelin for visceral fat, and the same principles apply here.
Monitoring also includes fasting glucose, since growth hormone affects glucose metabolism, and side effect tracking for fluid retention, joint discomfort, and other effects. Baseline labs, follow-up testing, and contraindication screening (including cancer history) are all part of responsible growth hormone peptide therapy.
The Regulatory Reality
The compounding availability of these peptides has been in flux in 2026, as we covered in the FDA peptide crackdown post. Sermorelin has held a more stable position due to its prior FDA approval. CJC-1295 and ipamorelin have been subject to the shifting regulatory picture and the ongoing review process. This is an area where current verification matters, and where a responsible clinic tracks the present status rather than relying on last year’s information. The foundational science is covered in our earlier physician’s guide to peptide therapy.
How We Approach the Choice
At Towsen Clinic, the growth hormone peptide decision starts with the patient’s goal and health profile, then matches the mechanism to that goal, with proper monitoring and attention to the current regulatory status. The peptide program is detailed on the advanced peptide therapy page.
If you are considering growth hormone peptides and want to understand which option actually fits your goals rather than picking a name off a forum, schedule a consultation and we will work through the mechanisms, the trade-offs, and the current options for your situation.
